The trusted source for
healthcare information and
The National Cancer Institute is seeking to fund projects that identify key genes and gene products that are altered in human cancer and could potentially be exploited as intervention points or targets for the discovery of new cancer prevention or treatment drugs. Funding is available through the R21 and R01 mechanisms. The R21 grants will be made in amounts of up to $100,000 in direct costs for four budget modules per year for two years. Researchers at foreign and domestic for profit and non-profit organizations are eligible. The deadline for letter of intent is June 4, 2001, with an application deadline of July 12, 2001, for the current cycle, and letter of intent deadline of Feb. 5, 2002, with application deadline of March 13, 2002, for the next cycle. More information is available at: http://www.nci.nih.gov/initiatives/nonmam.html.